Ga naar hoofdinhoud
Vertaling in uitvoering — deze inhoud wordt in het Engels weergegeven terwijl uw taalversie wordt voorbereid.
Terug naar Discussies

Trends in Buprenorphine and Methadone Dispensing Among Medicare Advantage and Commercial Enrollees, 2019-2024

Healthcare
United States
Gestart August 27, 2026

This study examined national trends in methadone and buprenorphine dispensing among Medicare Advantage and commercial enrollees with opioid use disorder from 2019 to 2024, characterizing differences by insurance type, age, and dual eligibility

Bronartikel

Stelling toevoegen Analyse 0/5
Need to find a specific claim? Search all statements.
🗳️ Join the conversation
10 stellingen om op te stemmen • Your perspective shapes the analysis
📊 Progress to Consensus Analysis Need: 7+ participants, 20+ votes, 3+ votes per statement
Participants 0/7
Statements (10+ recommended) 10/10
Total Votes 0/20
💡 Progress updates live here. Final readiness is confirmed when all three requirements are met.

Your votes count

No account needed — your votes are saved and included in the consensus analysis. Create an account to track your voting history and add statements.

CLAIM Geplaatst door admin • Aug 27, 2026
Access to both buprenorphine and methadone should be expanded for all enrollees to address opioid use disorder effectively.

Vertaling in behandeling

Vote options for this statement: agree, disagree, or unsure
💬 Discussie bekijken
Be first to respond
Vote to see results
CLAIM Geplaatst door admin • Aug 27, 2026
The age demographic of enrollees significantly influences the type of opioid treatment they receive.

Vertaling in behandeling

Vote options for this statement: agree, disagree, or unsure
💬 Discussie bekijken
Be first to respond
Vote to see results
CLAIM Geplaatst door admin • Aug 27, 2026
Buprenorphine dispensing among Medicare Advantage enrollees has significantly increased from 2019 to 2024.

Vertaling in behandeling

Vote options for this statement: agree, disagree, or unsure
💬 Discussie bekijken
Be first to respond
Vote to see results
CLAIM Geplaatst door admin • Aug 27, 2026
Dual-eligible individuals have the highest rates of buprenorphine dispensing compared to other groups.

Vertaling in behandeling

Vote options for this statement: agree, disagree, or unsure
💬 Discussie bekijken
Be first to respond
Vote to see results
CLAIM Geplaatst door admin • Aug 27, 2026
Insurance type should not dictate the quality of care for individuals with opioid use disorder.

Vertaling in behandeling

Vote options for this statement: agree, disagree, or unsure
💬 Discussie bekijken
Be first to respond
Vote to see results
CLAIM Geplaatst door admin • Aug 27, 2026
Methadone dispensing has declined sharply among commercial enrollees during the same period.

Vertaling in behandeling

Vote options for this statement: agree, disagree, or unsure
💬 Discussie bekijken
Be first to respond
Vote to see results
CLAIM Geplaatst door admin • Aug 27, 2026
Regulatory barriers continue to hinder equitable access to methadone for those in need.

Vertaling in behandeling

Vote options for this statement: agree, disagree, or unsure
💬 Discussie bekijken
Be first to respond
Vote to see results
CLAIM Geplaatst door admin • Aug 27, 2026
Both Medicare Advantage and commercial plans should collaborate to improve treatment accessibility for opioid use disorder.

Vertaling in behandeling

Vote options for this statement: agree, disagree, or unsure
💬 Discussie bekijken
Be first to respond
Vote to see results
CLAIM Geplaatst door admin • Aug 27, 2026
The rise in buprenorphine use indicates a shift towards more effective treatment options for opioid use disorder.

Vertaling in behandeling

Vote options for this statement: agree, disagree, or unsure
💬 Discussie bekijken
Be first to respond
Vote to see results
CLAIM Geplaatst door admin • Aug 27, 2026
Commercial enrollees experience barriers to accessing methadone treatment due to insurance restrictions.

Vertaling in behandeling

Vote options for this statement: agree, disagree, or unsure
💬 Discussie bekijken
Be first to respond
Vote to see results

💡 How This Works

  • • Add Statements: Post claims or questions (10-500 characters)
  • • Vote: Agree, Disagree, or Unsure on each statement
  • • Respond: Add detailed pro/con responses with evidence
  • • Consensus: After enough participation, analysis reveals opinion groups and areas of agreement

Society Speaks is open and independent. Your support keeps civic discussion free from advertising and commercial influence.

Support us